NEWS

Get the news about us and our portfolio!

Show: All Aravis News Portfolio News
aravis news image

September 5, 2017

Novimmune Receives Rare Pediatric Disease Designation from the FDA for its Lead Drug emapalumab

Providing eligibility is confirmed at the time of approval of emapalumab for the treatment of primary Hemophagocytic Lymphohistiocytosis (HLH), Novimmune would qualify for a rare pediatric disease priority review voucher

Geneva, Switzerland, 5th September, 2017 – Novimmune SA, a privately held Swiss biopharmaceutical company, announced today that the Food and Drug Administration of the US (FDA) has granted Rare Pediatric Disease Designation to its lead compound emapalumab for the treatment of primary HLH as a drug for a “rare pediatric disease”. Priority review vouchers are awarded upon the FDA approval of an eligible drug for a rare pediatric disease. In addition to the Rare Pediatric Disease designation, emapalumab has Orphan Drug designation in both the US and Europe, has received FDA’s Breakthrough Therapy designation, and has been granted eligibility for the European Medicines Agency’s PRIME scheme.

“We are delighted to have…

READ MORE

Providing eligibility is confirmed at the time of approval of emapalumab for the treatment of primary Hemophagocytic Lymphohistiocytosis (HLH), Novimmune would qualify for a rare pediatric disease priority review voucher

Geneva, Switzerland, 5th September, 2017 – Novimmune SA, a privately held Swiss biopharmaceutical company, announced today that the Food and Drug Administration of the US (FDA) has granted Rare Pediatric Disease Designation to its lead compound emapalumab for the treatment of primary HLH as a drug for a “rare pediatric disease”. Priority review vouchers are awarded upon the FDA approval of an eligible drug for a rare pediatric disease. In addition to the Rare Pediatric Disease designation, emapalumab has Orphan Drug designation in both the US and Europe, has received FDA’s Breakthrough Therapy designation, and has been granted eligibility for the European Medicines Agency’s PRIME scheme.

“We are delighted to have been granted this special designation for our emapalumab program,” said Chairman and Chief Executive Eduard Holdener. “We are looking forward to working with the regulatory authorities to make this medicine available to patients with this devastating disease as soon as possible. This priority review voucher is also precious as it can be used to secure the priority review of another program with the FDA and may be transferred between companies.”

About HLH and emapalumab
HLH is a hyperinflammatory syndrome characterized by uncontrolled and aberrant activation of the immune system and a life-threatening cytokine storm presenting with non-remitting fever, reduction in the number of blood cells and impaired coagulation potentially leading to death. Two forms of HLH are described: primary HLH is genetically determined and is typically diagnosed in infants and young children, while secondary HLH occurs on a background of a rheumatic/inflammatory disease, a malignancy or an infection.

Mortality in patients with primary and secondary HLH remains high, despite the use of aggressive immune-chemotherapy.

Emapalumab is a fully human, anti-interferon-gamma (IFNγ) monoclonal antibody discovered and developed by Novimmune. The biological activity of IFNγ, which is considered to have a pivotal pathogenic role in HLH, is neutralized by emapalumab, the first targeted therapy for this disease.

Novimmune SA
14 Chemin des Aulx
1228 Plan-Les-Ouates
Geneva, Switzerland
+41 22 839 71 41 Tel
+41 22 839 71 43 Fax
www.novimmune.com

About Novimmune
Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and runs a Clinical and Commercial Development Center in Basel. The company currently employs 130 people. More information is available on the company website at www.novimmune.com.

Contact:
Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com

Aravis News

August 12, 2017

Neue Zürcher Zeitung: Aravis Growth is the only direct fund addressing the growth phase of Swiss Startups

Samstag, 12.August 2017 Neue Zürcher Zeitung FOKUS DER WIRTSCHAFT 29

Die Politik sorgt sich um die Finanzierung von Jungunternehmen. Jüngst stellte sich gar ein Bundesrat in den Dienst eines neuen Risikokapitalfonds.
Brauchen die Startup-Investoren tatsächlich so viel Zuneigung?

Lesen Sie den ganzen Artikel in der beigelegten PDF Datei.

 

Aravis News

June 1, 2017

Evolva in contract negotiations with the US government for funding to advance nootkatone against Zika

Reinach, June 2017 – Evolva (SIX: EVE) confirms a media report stating that the Company is negotiating a sole-source contract with the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development and EPA registration of Evolva’s nootkatone product to help in the fight against the mosquitoes that transmit Zika virus. No further details can be provided at this time.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this…

READ MORE

Reinach, June 2017 – Evolva (SIX: EVE) confirms a media report stating that the Company is negotiating a sole-source contract with the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development and EPA registration of Evolva’s nootkatone product to help in the fight against the mosquitoes that transmit Zika virus. No further details can be provided at this time.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

About nootkatone01

Nootkatone is a citrus ingredient that is characteristically associated with grapefruit. It can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the Nootka cypress), or produced on an industrial scale from brewing via yeast fermentation. Nootkatone is being tested against a variety of biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease, but also the mosquitoes contributing to the spread of Zika, chikungunya, dengue and West Nile viruses, as well as head lice, bed bugs, and other biting insects.

About Zika virus

Zika virus disease (Zika) is a disease caused by Zika virus that is spread to people primarily through the bite of an infected Aedes species mosquito. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). Because the symptoms of Zika are similar to those of many other diseases, many cases may not have been recognised.

Contact Details

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 20 35

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Aravis News

May 16, 2017

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United…

AMSTERDAM, NETHERLANDS – May 16th, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its HydraSpace™ spacer technology has been granted by the United States Patent and Trademark Office (US 9,636,421 B2).

With the granting of this patent, Synaffix has secured end-to-end patent protection of its ADC technology platform, embodied by a growing portfolio of granted patents that now cover all three core areas of Synaffix ADC technology including GlycoConnect™, HydraSpace™ and metal-free click chemistry.

HydraSpace™ is a compact and highly polar spacer, which has consistently demonstrated the ability to significantly enhance ADC stability (reduced aggregation) and expand the therapeutic index of an ADC, beyond what is achieved by GlycoConnect™ alone. HydraSpace™ was originally designed to enable efficient…

READ MORE

AMSTERDAM, NETHERLANDS – May 16th, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its HydraSpace™ spacer technology has been granted by the United States Patent and Trademark Office (US 9,636,421 B2).

With the granting of this patent, Synaffix has secured end-to-end patent protection of its ADC technology platform, embodied by a growing portfolio of granted patents that now cover all three core areas of Synaffix ADC technology including GlycoConnect™, HydraSpace™ and metal-free click chemistry.

HydraSpace™ is a compact and highly polar spacer, which has consistently demonstrated the ability to significantly enhance ADC stability (reduced aggregation) and expand the therapeutic index of an ADC, beyond what is achieved by GlycoConnect™ alone. HydraSpace™ was originally designed to enable efficient attachment of the most challenging hydrophobic payloads, such as pyrrolobenzodiazepines (PBDs), to an antibody. Additionally, the branching capability of HydraSpace™ enables the dualwarhead ADC format, which is characterized by the attachment of two distinct payload types to the same antibody. This approach provides the possibility to deliver two different mechanisms of action to the same cell, which may represent a key strategy in the eradication of cancer stem cells and the treatment of multi-drug resistant forms of cancer.

“HydraSpace™ has confirmed our expectations as it has demonstrated its potential across numerous comparative studies, including against other mainstream site-specific conjugation technologies. As such, it represents a key differentiator for ADC product candidates being developed by our collaborators” said Peter van de Sande, CEO of Synaffix who added, “with the HydraSpace™ patent now granted, we have secured patent protection through at least 2035 for products developed using our technology.”

About GlycoConnect™ and HydraSpace™ Platforms

The Synaffix technology platforms include GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace™, the ADC-enhancing spacer technology. GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an ADC on its own.The highly polar properties of HydraSpace™ improve the solubility and stability of the payload and the resulting ADC product, thus enhancing further the therapeutic index of the ADC. Both technologies have demonstrated compatibility with all ADC payload classes and all IgG isotypes and can be applied directly to an existing antibody without any engineering.

About Synaffix BV

Synaffix BV is a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms.

As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure™.

Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures, the strategic corporate venture capital fund of Merck.

For more information, please visit the website at www.synaffix.com.

Synaffix BV Contact
Anthony DeBoer
Director, Business Development
bd@synaffix.com

Aravis News

May 3, 2017

UroGen Pharma Announces Pricing of Initial Public Offering

RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) — UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol “URGN.” In addition, UroGen Pharma granted the underwriters a 30-day option to purchase up to an additional 671,005 ordinary shares. The offering is expected to close on or about May 9, 2017, subject to customary closing conditions.

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as…

READ MORE

RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) — UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol “URGN.” In addition, UroGen Pharma granted the underwriters a 30-day option to purchase up to an additional 671,005 ordinary shares. The offering is expected to close on or about May 9, 2017, subject to customary closing conditions.

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 3, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About UroGen Pharma Ltd.

UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. Moreover, UroGen Pharma has recently completed a worldwide licensing agreement with Allergan Pharmaceuticals International Limited, a wholly owned subsidiary of Allergan plc, for the use of RTGel with neurotoxins for the treatment of overactive bladder and related conditions. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.

Forward Looking Statements

This press release contains forward-looking statements, including with respect to the expected closing of the initial public offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including that the conditions to the closing of the initial public offering are not satisfied. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.

CONTACT:
Gary Titus, UroGen Pharma Ltd.
689 Fifth Avenue, 14th Floor
New York, NY 10022
garyt@urogen.com
646-768-9531

Stephanie Carrington, ICR, Inc.
685 Third Avenue 2nd Floor
New York, NY 10017
stephanie.carrington@icrinc.com
646-277-1282

Aravis News

April 3, 2017

Evolva announces long-term commercial agreement with Cargill. EverSweetTM next-generation stevia ingredient on track for 2018 launch

Evolva to establish global production hub in USA

Reinach, 3 April 2017 – Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage.

EverSweet™ is a next-generation stevia sweetener that solves both the stevia taste and Reb M & Reb D scaleability challenges. EverSweet™ is brewed to produce large quantities of the most sought-after sweetness ingredients found in the stevia leaf, Reb M and Reb D. The stevia leaf contains only minute quantities of these ingredients. EverSweet™ also delivers better sweetness intensity, faster sweetness onset and improved sweetness quality – without the bitterness or off-note aftertaste common to existing stevia sweeteners. Evolva estimates the total addressable market to be worth around USD 4…

READ MORE

Evolva to establish global production hub in USA

Reinach, 3 April 2017 – Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage.

EverSweet™ is a next-generation stevia sweetener that solves both the stevia taste and Reb M & Reb D scaleability challenges. EverSweet™ is brewed to produce large quantities of the most sought-after sweetness ingredients found in the stevia leaf, Reb M and Reb D. The stevia leaf contains only minute quantities of these ingredients. EverSweet™ also delivers better sweetness intensity, faster sweetness onset and improved sweetness quality – without the bitterness or off-note aftertaste common to existing stevia sweeteners. Evolva estimates the total addressable market to be worth around USD 4 billion.

Evolva will receive up to 30% of the EverSweet™ business, determined as a function of the strain efficiencies achieved. Evolva has the right to ask Cargill to support some of Evolva’s early cashflow commitments at a favourable interest rate, however under the new agreement Evolva will not receive any further milestone payments from Cargill.

EverSweetTM next generation sweetener will initially be produced at a fermentation facility on Cargill’s Blair, Nebraska campus that will be retrofitted for this purpose. The facility will be operated by Cargill and additionally be used for the fermentation of other Evolva products. In parallel, Evolva will build and operate a new state-of-the-art bioprocessing facility on adjacent land leased from Cargill. This bioprocessing facility will manufacture Evolva products such as nootkatone and resveratrol and is expected to come online in 2019. Together, this integrated infrastructure will provide Evolva with a global hub for the production of high value specialty ingredients.

Evolva CEO Neil Goldsmith said, “EverSweet™ is coming to market, and given it succeeds as we expect it to, Evolva will see 30% of the upside whilst mitigating some of our initial cash outflows. Plus our planned US production hub, working alongside Cargill, provides the foundation for truly scaleable, low cost, high quality, production for Evolva’s other key products.”

The production strategy provides a de-risked route for Evolva to establish its own low cost production of specialty ingredients through a collaboration with one of the world’s pre-eminent bioprocessing companies. Locating these operations in Blair, Nebraska also allows Evolva to leverage and access key resources such as Cargill’s centralised infrastructure, a skilled local labour pool, and a long-term supply of renewable resources from US farm inputs (corn, in particular). A number of world-class producers like Novozymes, Corbion and Evonik operate on the same Cargill campus in Blair.

Once completed, the Blair production facilities will play a pivotal role in accelerating the reduction of the cost-of-goods-sold for Evolva’s products, increasing the company’s long-term profitability. The facilities are expected to have sufficient capacity to generate an estimated USD 50 million-plus in annual product revenues for Evolva, over and above Evolva’s share of EverSweetTM profits, and provide room for further expansion.

Over the next three years, principally in 2018 and 2019, Evolva expects to invest an estimated USD 60 million in the combined fermentation and bioprocessing facilities for EverSweet™ and its other products. The recent CHF 30 million equity commitment from Yorkville serves as a foundation for this investment and Evolva expects to secure an additional project financing package of around CHF 30 million by end 2017, which will enable full execution of the plans.

Press/analyst meeting at 14.00 CET on 3 April 2017

Evolva will host a press and analyst meeting at SIX Convention Point, Selnaustrasse 30 Zürich, today at 2PM CET. The presentation is available on Evolva’s website. The meeting will also be accessable by phone under the following numbers:

+41 (0)58 310 5000 (Europe)
+44 (0)203 059 5862 (UK)
+1 (1)631 570 5613 (USA)

A replay will be available as a podcast for 2 weeks after the call. The link to the podcast will be posted on Evolva’s website.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

Contact Details

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Oliver Walker, CFO
oliverw@evolva.com
+ 41 61 485 2034

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 20 35

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.03

Aravis News

March 30, 2017

Symetis and Boston Scientific reach USD 435 million purchase agreement

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Ecublens, Switzerland, 30 March 2017 – Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment…

READ MORE
  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Ecublens, Switzerland, 30 March 2017 – Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

Contact

Symetis
Khaled Bahi – Chief Financial Officer
+41 (0) 21 651 01 60
investors@symetis.com

Weber Shandwick
Alphonse Daudré-Vignier
+41 (0) 79 127 63 58
adaudre-vignier@webershandwick.com

About Symetis

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.
Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit www.symetis.com

Aravis News

March 9, 2017

Evolva achieves second milestone in fragrance & flavour alliance with Takasago

Reinach, 9 March 2017 – Evolva (SIX: EVE) today announces reaching the second technical milestone under the multi-year R&D alliance with Takasago. This achievement brings the project closer to the launch of the target ingredients and prompts a total milestone payment of USD 1 million to Evolva as well as the continuation of the collaboration into the next phases.

The aim of the collaboration is to co-develop novel fermentation routes to produce several undisclosed ingredients with broad applications in the fragrance and flavour industry. Evolva and Takasago are applying Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable and cost-effective production of the ingredients.

Based on the timing of the progress and the contractual agreement, the revenue was recognised in Evolva’s 2016 accounts.

About Takasago

Takasago International Corporation is a world leader in the flavour and…

READ MORE

Reinach, 9 March 2017 – Evolva (SIX: EVE) today announces reaching the second technical milestone under the multi-year R&D alliance with Takasago. This achievement brings the project closer to the launch of the target ingredients and prompts a total milestone payment of USD 1 million to Evolva as well as the continuation of the collaboration into the next phases.

The aim of the collaboration is to co-develop novel fermentation routes to produce several undisclosed ingredients with broad applications in the fragrance and flavour industry. Evolva and Takasago are applying Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable and cost-effective production of the ingredients.

Based on the timing of the progress and the contractual agreement, the revenue was recognised in Evolva’s 2016 accounts.

About Takasago

Takasago International Corporation is a world leader in the flavour and fragrance industry. Founded in Japan in 1920, Takasago has developed flavours and fragrances for some of the world’s most successful food, beverage, fine fragrance, household and personal care products. Takasago is the only Asia-based global flavour and fragrance company specialising in nature-identical and asymmetric molecules using unique chiral technologies. For more information check at www.takasago.com.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

Contact Details

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Oliver Walker
oliverw@evolva.com
+ 41 61 485 2034

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Aravis News

February 20, 2017

New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs

AMSTERDAM, NETHERLANDS, February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

The data result from a series of preclinical studies performed in rodents and non-human primates, in a comparative assessment, by an undisclosed collaborator. In these studies different ADCs comprising the same antibody and cytotoxic payload were assembled with either Synaffix’ proprietary GlycoConnect™ and HydraSpace™ technologies or a cysteineengineered methodology.

“After showing superiority vs the earlier conjugation methodologies used in the currently marketed ADCs, our proprietary technology has now demonstrated enhanced therapeutic index also vs what is widely regarded as the most advanced…

READ MORE

AMSTERDAM, NETHERLANDS, February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

The data result from a series of preclinical studies performed in rodents and non-human primates, in a comparative assessment, by an undisclosed collaborator. In these studies different ADCs comprising the same antibody and cytotoxic payload were assembled with either Synaffix’ proprietary GlycoConnect™ and HydraSpace™ technologies or a cysteineengineered methodology.

“After showing superiority vs the earlier conjugation methodologies used in the currently marketed ADCs, our proprietary technology has now demonstrated enhanced therapeutic index also vs what is widely regarded as the most advanced clinical-stage, site-specific ADC technology” said Floris van Delft, CSO of Synaffix. “With more than ten engineered-cysteine based ADC programs currently in clinical trials, the new data cultivate further confidence towards the clinical performance of ADCs built using our proprietary technology, as we prepare for the manufacturing of the first clinical batches that will be delivered to patients next year.”

Synaffix will present the supporting data during a plenary presentation at the World ADC event in Berlin on Tuesday, February 21 at 5:00pm CET.

About GlycoConnect™ and HydraSpace™ Platforms

Synaffix technology includes GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace™, the ADC-enhancing spacer technology. GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an ADC on its own. The highly polar properties of HydraSpace™ improve the solubility and stability of the resulting ADC product, thus further enhancing the therapeutic index of the ADC. Both technologies have demonstrated compatibility with all ADC payload classes and all IgG isotypes without requiring antibody engineering.

About Synaffix BV

Synaffix BV is a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms.

As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure™.

Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures, the strategic corporate venture capital fund of Merck.

For more information, please visit the website at www.synaffix.com.

Synaffix BV Contact

Anthony DeBoer
Director, Business Development
bd@synaffix.com

Aravis News

January 11, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with…

  • Namacizumab is a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the cannabinoid 1 receptor (CB1) in an inactive conformation.
  • Namacizumab is being developed to treat large unmet medical needs in fibrotic and metabolic disease, including non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
  • The double blind, placebo controlled, dose ranging Phase 1 clinical trial will include a Single Ascending Dose Study in healthy volunteers and a Multiple Ascending Dose Study in non-alcoholic fatty liver disease (NAFLD) patients, assessing outcomes of key biomarkers.
  • Bird Rock Bio will be working with GE Healthcare on scale-up and down stream process optimization, subcutaneous formulation, and 1000 liter cGMP manufacture of namacizumab in preparation for Phase 2 clinical trials.
  • Bird Rock Bio has entered into a collaboration and option agreement, pursuant to which Janssen Pharmaceuticals, Inc. has…
READ MORE
  • Namacizumab is a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the cannabinoid 1 receptor (CB1) in an inactive conformation.
  • Namacizumab is being developed to treat large unmet medical needs in fibrotic and metabolic disease, including non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
  • The double blind, placebo controlled, dose ranging Phase 1 clinical trial will include a Single Ascending Dose Study in healthy volunteers and a Multiple Ascending Dose Study in non-alcoholic fatty liver disease (NAFLD) patients, assessing outcomes of key biomarkers.
  • Bird Rock Bio will be working with GE Healthcare on scale-up and down stream process optimization, subcutaneous formulation, and 1000 liter cGMP manufacture of namacizumab in preparation for Phase 2 clinical trials.
  • Bird Rock Bio has entered into a collaboration and option agreement, pursuant to which Janssen Pharmaceuticals, Inc. has the exclusive right to acquire the company following the Phase 1 data readout.

La Jolla, CA, January 11, 2017 — Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that it has received approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). In addition, Bird Rock Bio has entered into an agreement with GE Healthcare for process development, formulation, and manufacture of namacizumab in preparation for Phase 2 studies. Furthermore, the Phase 1 trial, process development, and Phase 2 preparation will be funded under a collaboration and option agreement with Janssen Pharmaceuticals, Inc.

The trial is anticipated to provide important safety, tolerability and biomarker efficacy data for namacizumab to support differentiated clinical potential in fibrotic and metabolic disease. As a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the inactive conformation of CB1, namacizumab has the potential to build on the significant historic mechanistic and clinical data on the modulation of CB1 in disease.

“As we prepare for future phases of development, we will be working with GE Healthcare on downstream process development, subcutaneous formulation, and clinical scale manufacturing,” said Paul Grayson, Bird Rock Bio’s CEO. “While we are conducting the SAD and MAD clinical trial, we will also be completing supportive chronic toxicology and bioequivalence studies to be fully prepared for the next phases of clinical development.”

Bird Rock Bio has entered into a collaboration and option agreement with Janssen Pharmaceuticals, Inc. pursuant to which Janssen has an exclusive option to acquire the company following the Phase 1 data readout. “We believe that Janssen’s expertise in the development, manufacture, and commercialization of biologic therapeutics will allow Bird Rock to accelerate the development of namacizumab,” added Grayson. “We look forward to working with Janssen on this important Phase 1 program. If the Phase 1 data are positive, it will signify a meaningful advancement for this novel potential therapeutic for NASH, and an important event for Bird Rock Bio’s shareholders.”

About Namacizumab

Discovered internally through Bird Rock Bio’s proprietary iCAPS platform, namacizumab is scheduled to be the first and only known NAMA to the CB1 receptor to be entering clinical trials. Namacizumab is a multi-modal therapeutic candidate with fibrotic, inflammatory and metabolic mechanisms of action. This provides for the opportunity for namacizumab to have significant potential across a broad range of fibrotic and metabolic diseases including large unmet medical conditions such as NASH and diabetic nephropathy.

About iCAPS

Bird Rock Bio’s iCAPS platform, the leading GPCR allosteric antibody drug discovery platform, can isolate and present functional GPCRs in the correct confirmation to identify selective monoclonal antibody allosteric modulators. GPCRs are a valuable class of drug targets but have been largely unexplored in antibody discovery because of the difficulty in isolating GPCRs in the correct conformation and functional form.

About Bird Rock Bio, Inc.

Backed by leading biotechnology venture investors, Bird Rock Bio’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first in class or best in class molecules with strong clinical and commercial differentiation. The Company is focused on developing proprietary antibodies for fibrotic, metabolic and inflammatory diseases, including RA, SA, NASH and diabetic nephropathy. Bird Rock Bio’s science team is experienced with translating pioneering research into promising therapeutics with potential deep pharmacoeconomic benefits. For more, visit www.birdrockbio.com.

Media Contact:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
+1.858.344.8091

aravis news image

December 5, 2016

Novimmune grants Genentech an exclusive option to license NI-0101, its anti-TLR4 monoclonal antibody for the treatment of rheumatoid…

GENEVA, 05 December 2016 — Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of NI-0101, an anti-TLR4 (Toll-like receptor 4) monoclonal antibody, for the potential treatment of rheumatoid arthritis and other autoimmune diseases.

Under the terms of the agreement, Genentech receives an exclusive option to license all rights to develop and commercialize NI-0101, pending the results of a Phase 2a proof-of-concept study in patients with rheumatoid arthritis to be conducted by Novimmune.

If Genentech exercises its option under the agreement, Genentech would be responsible for further development and potential commercialization of NI-0101 and Novimmune would receive an undisclosed payment. In addition, Novimmune would be eligible to receive milestone…

READ MORE

GENEVA, 05 December 2016 — Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of NI-0101, an anti-TLR4 (Toll-like receptor 4) monoclonal antibody, for the potential treatment of rheumatoid arthritis and other autoimmune diseases.

Under the terms of the agreement, Genentech receives an exclusive option to license all rights to develop and commercialize NI-0101, pending the results of a Phase 2a proof-of-concept study in patients with rheumatoid arthritis to be conducted by Novimmune.

If Genentech exercises its option under the agreement, Genentech would be responsible for further development and potential commercialization of NI-0101 and Novimmune would receive an undisclosed payment. In addition, Novimmune would be eligible to receive milestone payments upon achievement of certain predetermined clinical, regulatory and commercial milestones, as well as royalties on worldwide net sales resulting from the license agreement. Further financial details have not been disclosed.

This is the second agreement between the two companies. In July 2010, Novimmune and Genentech entered into an exclusive licensing agreement to discover and develop antibodies that target the IL-17 signaling pathway for the treatment of autoimmune diseases.

“We are excited to have now signed a second agreement with Genentech to develop a medicine for rheumatoid arthritis, where there is significant unmet need and the potential to become the first personalized medicine in rheumatoid arthritis” said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 122 people. More information is available on the company website at www.novimmune.com.

Contact:

Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com

aravis news image

October 27, 2016

Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab

  • Namacizumab is a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the cannabinoid 1 receptor (CB1) in an inactive conformation.
  • Namacizumab is being developed to treat large unmet medical needs in fibrotic and metabolic disease, including non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
  • The double blind, placebo controlled, dose ranging Phase 1 clinical trial will include a Single Ascending Dose Study in healthy volunteers and a Multiple Ascending Dose Study in non-alcoholic fatty liver disease (NAFLD) patients, assessing outcomes of key biomarkers.
  • The results are anticipated by Q4 2017 and are expected to support later stage clinical trials in multiple indications.
  • Namacizumab was discovered internally through Bird Rock Bio’s proprietary iCAPS platform, which is specialized to enable the discovery of functional antibodies to G protein coupled receptors.

La Jolla,…

READ MORE
  • Namacizumab is a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the cannabinoid 1 receptor (CB1) in an inactive conformation.
  • Namacizumab is being developed to treat large unmet medical needs in fibrotic and metabolic disease, including non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
  • The double blind, placebo controlled, dose ranging Phase 1 clinical trial will include a Single Ascending Dose Study in healthy volunteers and a Multiple Ascending Dose Study in non-alcoholic fatty liver disease (NAFLD) patients, assessing outcomes of key biomarkers.
  • The results are anticipated by Q4 2017 and are expected to support later stage clinical trials in multiple indications.
  • Namacizumab was discovered internally through Bird Rock Bio’s proprietary iCAPS platform, which is specialized to enable the discovery of functional antibodies to G protein coupled receptors.

La Jolla, CA, October 27, 2016 — Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that today it has requested approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). The trial is anticipated to provide important safety, tolerability and biomarker efficacy data for namacizumab to support differentiated clinical potential in fibrotic and metabolic disease. As a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the inactive conformation of CB1, namacizumab has the potential to build on the significant historic mechanistic and clinical data on the modulation of CB1 in disease.

According to Paul Grayson, Bird Rock Bio’s CEO, “2016 has been a year of exceptional progress for our Company. This submission for the first in human clinical trial for namacizumab represents the culmination of four years of extraordinary efforts by our scientific and development team. Achievement of this milestone for a novel and highly differentiated biologic that can address several of the world’s largest emerging medical needs provides tremendous opportunity and excitement for our organization, partners and investors. ”

Namacizumab‘s Unique Position as the Only Therapeutic Antibody to CB1.

CB1 modulation has been extensively researched pre-clinically and clinically by many of the largest pharmaceutical companies in metabolic and fibrotic diseases and has demonstrated substantial efficacy potential. Clinical development for small molecule CB1 modulators had been largely abandoned due to the emergence of adverse effects that were associated with their penetration of the central nervous system (CNS). As antibodies are large molecule proteins that typically do not penetrate the blood brain barrier, and thus are expected to avoid the CNS, Bird Rock Bio selected CB1 as a top target for its antibody discovery.

Following the groundbreaking discovery as the only known negative allosteric modulating antibody to CB1, namacizumab has been evaluated in multiple preclinical safety studies which have confirmed the antibody to be restricted to peripheral tissues and avoidance of the CNS. In a large IND-enabling toxicology study recently completed, as much as 75 times the anticipated therapeutic dose of namacizumab was administered with no significant adverse effects. These favorable outcomes have been a key part of the advancement of namacizumab into clinical development.

Namacizumab Phase 1 Clinical Trial.

A single ascending dose (SAD) trial in 24 healthy volunteers will assess safety, tolerability, and pharmacokinetics. A multiple ascending dose (MAD) trial will be initiated following the safety review of the last SAD cohort and will include up to 60 non-alcoholic fatty liver disease (NAFLD) patients. Multiple clinically validated biomarkers such as de novo lipogenesis, liver fat and glucose tolerance will be assessed in the MAD trial. Data from the SAD and MAD are anticipated to be available in Q1 2017 and Q4 2017 respectively.

The trial was designed in collaboration with Bird Rock Bio’s clinical advisory board, which includes leading NASH experts, Scott Friedman, MD (Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai), Rohit Loomba, MD (Professor of Medicine (with tenure) in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California, San Diego) and Stephen Harrison, MD LTC (Chief of Hepatology at Brooke Army Medical Center, Fort Sam Houston, TX).

According to Dr. Scott L. Friedman: “with its potential role in the metabolic, inflammatory, and fibrotic components of NASH, namacizumab is among the first drug candidates to address these 3 key features of the disease that drive clinical progression. As a monoclonal antibody, namacizumab has been shown in multiple pre-clinical studies to be safe and well tolerated and to not enter the central nervous system. There is currently no FDA approved treatment for NASH, a growing epidemic affecting up to 15 million people in the US and expected to become the leading cause of liver transplant by 2020.”

Additionally, NASH patients are at high risk of morbidity and mortality from cardiovascular comorbid disease. Unlike many of the alternative compounds currently in clinical development for NASH, namacizumab has the potential to favorably effect multiple cardiovascular and metabolic risk factors. Combined with its multimodal mechanistic profile, this potential safety enhancement is anticipated to be a strong competitive differentiator for namacizumab.

From a manufacturing standpoint, namacizumab has been efficiently produced in CHO-K1 cells, demonstrating favorable expression of approximately 2.8 grams per liter. Accordingly, manufacturing of clinical supply is complete for both the Phase 1a and Phase 1b trials (more than 2,100 vials of drug product) and is well positioned for late stage development and commercial needs.

“Having accomplished numerous critical development goals for namacizumab, Bird Rock Bio is well positioned to achieve major clinical milestones in 2017,” said Paul Grayson. “We look forward to providing additional updates in the near future.”

About Namacizumab

Discovered internally through Bird Rock Bio’s proprietary iCAPS platform, namacizumab is scheduled to be the first and only known NAMA to the CB1 receptor to be entering clinical trials. Namacizumab is a multi-modal therapeutic candidate with fibrotic, inflammatory and metabolic mechanisms of action. This provides for the opportunity for namacizumab to have significant potential across a broad range of fibrotic and metabolic diseases including large unmet medical conditions such as NASH and diabetic nephropathy.

About iCAPS

Bird Rock Bio’s iCAPS platform, the leading GPCR allosteric antibody drug discovery platform, can isolate and present functional GPCRs in the correct confirmation to identify selective monoclonal antibody allosteric modulators. GPCRs are a valuable class of drug targets but have been largely unexplored in antibody discovery because of the difficulty in isolating GPCRs in the correct conformation and functional form.

About Bird Rock Bio, Inc.

Backed by leading biotechnology venture investors, Bird Rock Bio’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first in class or best in class molecules with strong clinical and commercial differentiation. The Company is focused on developing proprietary antibodies for fibrotic, metabolic and inflammatory diseases, including RA, SA, NASH and diabetic nephropathy. Bird Rock Bio’s science team is experienced with translating pioneering research into promising therapeutics with potential deep pharmacoeconomic benefits. For more, visit www.birdrockbio.com.

Media Contact:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
+1.858.344.8091

 

aravis news image

October 27, 2016

ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

DUBLIN, Ireland, and REINACH, Switzerland, October 27th, 2016 – ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.DUBLIN, Ireland, and REINACH, Switzerland, October 27th, 2016 – ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use…

READ MORE

DUBLIN, Ireland, and REINACH, Switzerland, October 27th, 2016 – ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.DUBLIN, Ireland, and REINACH, Switzerland, October 27th, 2016 – ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

“Genome editing has many applications beyond drug discovery and development and making the CRISPR-Cas9 patents available to industrial biotechnology leaders such as Evolva is a growing and important part of our business. We are thus very pleased to include them in our expanding portfolio of licensees,” said Eric Rhodes, CEO of ERS Genomics.

“By combining modern genetics with traditional brewing, Evolva tries to overcome some of the challenges in producing natural ingredients for commercial use. Evolva uses proprietary technologies and is committed to gain access to complementary platforms that allow us to enhance the properties of the ingredients we produce, as well as their economics,” commented Neil Goldsmith, CEO of Evolva.

Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome editing tool.

Financial details of the agreement were not disclosed.

About ERS Genomics

ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

Contact ERS Genomics:

MacDougall, Biomedical Communications
Mario Brkulj or Dr. Stephanie May
Direct:  +49 89 2420 9345 or +49 89 2420 9344
E-Mail: mbrkulj@macbiocom.com or smay@macbiocom.com

Contact Evolva:

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken,IR
paulv@evolva.com
+ 41 61 485 2035

THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS. THE COMPANY ASSUMES NO RESPONSIBILITY TO UPDATE FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.

aravis news image

October 20, 2016

Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

AMSTERDAM, NETHERLANDS, October 20, 2016 – Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.

Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.

Floris van Delft, CSO at Synaffix said, “We are delighted that ADC Therapeutics has recognized the value of our proprietary antibodydrug conjugate technologies and has elected to incorporate Synaffix technology into one of its preclinical programs.”

“The experience of Synaffix and its partners has consistently confirmed that, in preclinical models, our proprietary GlycoConnect™ and HydraSpace™ technologies significantly improved both efficacy and…

READ MORE

AMSTERDAM, NETHERLANDS, October 20, 2016 – Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.

Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.

Floris van Delft, CSO at Synaffix said, “We are delighted that ADC Therapeutics has recognized the value of our proprietary antibodydrug conjugate technologies and has elected to incorporate Synaffix technology into one of its preclinical programs.”

“The experience of Synaffix and its partners has consistently confirmed that, in preclinical models, our proprietary GlycoConnect™ and HydraSpace™ technologies significantly improved both efficacy and safety as compared to other mainstream site-specific conjugation approaches.”

“We look forward to working closely with the ADC Therapeutics team to advance these promising therapeutics to the patients who need them.”

Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.

About GlycoConnect™ and HydraSpace™

The Synaffix technology platforms include GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace™, the antibody-drug conjugate enhancing spacer technology.

GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an antibody-drug conjugate on its own. The highly polar properties of HydraSpace™ improve the solubility and stability of the payload and the resulting antibody-drug conjugate product, thus enhancing further the therapeutic index of the antibody-drug conjugate.

Both technologies have demonstrated compatibility with all antibody-drug conjugate payload classes and all IgG isotypes without requiring antibody engineering.

About Synaffix BV

Founded in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure™. Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures, the strategic corporate venture capital fund of Merck.

For more information, please visit the website at www.synaffix.com.

Synaffix BV Contact
Anthony DeBoer
Director, Business Development
Tel: +31 620 773 194
bd@synaffix.com

aravis news image

August 18, 2016

Evolva publishes financial results for the first half of 2016 and provides business update

Text und PDFs wurden gekürzt und zusammengefasst!

Reinach, 18 August 2016 – Evolva (SIX: EVE) today announces its financial results for the period 1 January to 30 June 2016. The Powerpoint presentation and condensed half-year accounts are available on Evolva’s website.

Key highlights of 2016 to date:

  • Strong growth in sales pipeline for nootkatone, valencene and resveratrol.
  • Solid technical, regulatory and intellectual property progress on EverSweetTM
  • Increased focus on key products that address important unmet consumer needs
  • Resveratrol production bottlenecks removed
  • Resveratrol under development with US Navy for use as lightweight, fire resistant composite
  • Nootkatone proving to be efficacious against a wide range of key pests; safety data…
READ MORE

Text und PDFs wurden gekürzt und zusammengefasst!

Reinach, 18 August 2016 – Evolva (SIX: EVE) today announces its financial results for the period 1 January to 30 June 2016. The Powerpoint presentation and condensed half-year accounts are available on Evolva’s website.

Key highlights of 2016 to date:

  • Strong growth in sales pipeline for nootkatone, valencene and resveratrol.
  • Solid technical, regulatory and intellectual property progress on EverSweetTM
  • Increased focus on key products that address important unmet consumer needs
  • Resveratrol production bottlenecks removed
  • Resveratrol under development with US Navy for use as lightweight, fire resistant composite
  • Nootkatone proving to be efficacious against a wide range of key pests; safety data encouraging
  • Support from CDC and NIH for nootkatone use in insect control
  • Broadened commercial reach via Singapore sales office and extended distributor network
  • Driven product costs down significantly further, across the board
  • Achieved milestones in Takasago project
  • US passes new food labelling law that clarifies regulatory landscape for Evolva products

Financial highlights:

  • 1H 2016 revenues of CHF 3.7 million (1H 2015: CHF 8.3mn, of which CHF 4mn was non-recurring)
  • Product revenues doubled, albeit from a low base
  • Cash position of CHF 66.7 million on 30 June 2016

Please read more in the PDF files above!

 

 

aravis news image

August 10, 2016

Evolva’s collaboration with US Navy to focus on resveratrol-based composites Testing underway of materials fabricated from special formulation…

Reinach, 10 August 2016 – Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of composites.Reinach, 10 August 2016 – Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of…

READ MORE

Reinach, 10 August 2016 – Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of composites.Reinach, 10 August 2016 – Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of composites.

Currently available structural carbon composites are often unsuited for high-energy, high fire-risk applications such as fuel tanks, engine components, high-rise buildings, elevators, rockets, trains, and lithium battery casings, to name just a few.

The polymer resin matrix being tested for this new class of composite materials is made from a special formulation of Evolva’s resveratrol, which can be economically and sustainably manufactured on an industrial scale using advanced biotechnology and fermentation, converted to a thermosetting monomer, and then polymerised and shaped/moulded using standard fabrication techniques.

Prototype materials made from Evolva’s resveratrol have performed well in preliminary tests, exhibiting a number of advantages over existing fire-resistant materials. Resveratrol polymer composites are lighter than aluminium, halogen free, and able to withstand prolonged exposure to intense heat and flame impingement without combusting or structurally degrading. More testing is needed, but if results remain consistent it could usher in a new class of structural composite materials.

Over and above the benefits to the US Navy, there could be a broad spectrum of civilian applications (aviation, aerospace, automotive, public transport, construction, electronics, energy storage and transmission) and professionals (first responders, construction workers, miners, foundry workers, welders, mechanics) that stand to benefit from products fortified with these composites.

“Engineering with biology provides a way to produce a whole range of product innovations that would otherwise be impossible to achieve economically and sustainably,” said Evolva CEO Neil Goldsmith.

About resveratrol

Resveratrol is an ingredient found in certain plants that is associated with a range of functional effects when the plant is subjected to extreme stress from things like heat, dehydration, or disease. Many of the functional effects associated with resveratrol that are observed in nature are thought to be mediated by its induction of “survival” genes. Evolva’s resveratrol is produced using advanced biotechnology and yeast fermentation. It is made from natural and sustainable feedstocks and has a highly scalable, stable, traceable and reliable supply chain.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera,Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken,IR
paulv@evolva.com
+ 41 61 485 2035

THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS. THE COMPANY ASSUMES NO RESPONSIBILITY TO UPDATE FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.

aravis news image

July 28, 2016

Cornelius and Evolva bring new fermented resveratrol to market

Reinach,28 July 2016 – Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.Reinach,28 July 2016 – Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.
Resveratrol is an ingredient found in red grapes, blueberries, nuts and other plants. There is already a significant body of evidence showing that resveratrol can produce a positive impact on healthy-ageing variables like heart health, bone health, and blood-glucose control. Scientists have also found evidence in key biomarkers that resveratrol might slow the…

READ MORE

Reinach,28 July 2016 – Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.Reinach,28 July 2016 – Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.
Resveratrol is an ingredient found in red grapes, blueberries, nuts and other plants. There is already a significant body of evidence showing that resveratrol can produce a positive impact on healthy-ageing variables like heart health, bone health, and blood-glucose control. Scientists have also found evidence in key biomarkers that resveratrol might slow the progression of Alzheimer’s disease and mimic the effects of a calorie-restricted diet. Evolva’s resveratrol comes from a fermentation process, producing a high-purity ingredient free of any environmental contaminants.

Joy Thomas, technical manager, Cornelius Group said: “Most resveratrol on the market today comes from the Japanese knotweed plant. Evolva’s resveratrol is different and is manufactured via the fermentation of yeast, making it a pure product that is free of pesticides and other impurities that can be found in knotweed extracts.”
The fermented resveratrol from Evolva has a purity over 98 per cent and is suitable for a broad range of products from capsules and tablets for dietary supplements to more complex applications in foods, animal nutrition and personal care products. Cornelius has a strong position in these application markets. As the exclusive distributor for Evolva’s fermented resveratrol, Cornelius will supply the ingredient to the UK, Republic of Ireland, Denmark, Norway, Sweden and Finland foods market, countries with a total population 96 million.

Ms Thomas added “Consumers are now demanding formulations derived from natural sources. The clean label trend is now seen more as a consumer expectation, as well as an industry standard. Fermentation of Evolva’s resveratrol is a natural process and supports the current market and consumer trends”.

Evolva CEO Neil Goldsmith, said: “Much of the resveratrol sold today is made from knotweed, which results in a lack of control over the standard of crop. The benefit of using the fermentation process is that it ensures the quality of the ingredient. Manufacturing resveratrol through the fermentation of yeast offers us, and our customers, peace of mind as it’s made from natural and sustainable feedstocks and has a stable, traceable and reliable supply chain.”

This distribution agreement does not change Evolva’s revenue guidance for 2016.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

About Cornelius

Cornelius is an independent European manufacturer and distributor of branded and own brand speciality chemicals, raw materials and ingredients supporting new product development in Health & Nutrition, Care Products and Industrial markets.

Contact Details Evolva

Neil Goldsmith,CEO
neilg@evolva.com
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO
jakobdh@evolva.com
+ 41 61 485 2034

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS. THE COMPANY ASSUMES NO RESPONSIBILITY TO UPDATE FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS.

aravis news image

July 25, 2016

Evolva’s nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus

Reinach, 25 July 2016 – Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.Reinach, 25 July 2016 – Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.

Zika is one of a number of mosquito-borne viruses, which include both dengue and chikungunya, that are transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The…

READ MORE

Reinach, 25 July 2016 – Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.Reinach, 25 July 2016 – Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.

Zika is one of a number of mosquito-borne viruses, which include both dengue and chikungunya, that are transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The World Health Organisation and the US Centers for Disease Control and Prevention (CDC) have declared the Zika virus a public health emergency. Zika is associated with potentially severe neuropathogenic and neurodevelopmental conditions in humans.
Studies will be conducted at Colorado State University (CSU) in Fort Collins, Colorado, under NIAID’s preclinical services program. CSU researchers will test both the repellency and insecticidal properties of nootkatone against mosquitoes infected with the Zika virus. Data from these studies will supplement Evolva’s ongoing research to fulfil the US Environmental Protection Agency’s requirements for the commercial launch of nootkatone.

This NIH-sponsored research represents the latest expansion of Evolva’s nootkatone work with the US government, which began as a collaboration with the CDC. Evolva and the CDC initially examined nootkatone’s effectiveness for tick control as a novel approach to reduce the spread of tick-borne diseases such as Lyme disease. In late February 2016, Evolva’s nootkatone collaboration with the CDC expanded to include an additional focus on mosquitoes, including those that transmit Zika, chikungunya, dengue and West Nile viruses.

CDC research has already shown that nootkatone both repels and kills Aedes aegypti, the mosquito that transmits Zika and yellow fever, and the black-legged tick, Ixodes scapularis which transmits Lyme disease. Nootkatone appears to have a mode of action distinct from that of currently used pesticides, and therefore, could potentially be valuable for mitigating pesticide resistance in mosquito vectors.
The NIH will sponsor CSU’s studies directly, and as such there will not be any near term impact on Evolva’s costs or revenues.

About nootkatone

Nootkatone is a citrus ingredient that is characteristically associated with grapefruit. It can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (Nootka cypress), or produced on an industrial scale from brewing via yeast fermentation. Nootkatone is being tested against a variety of biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease, but also the mosquitoes contributing to the spread of Zika, chikungunya, dengue and West Nile viruses, as well as head lice, bed bugs and other biting insects.

About Lyme disease and Zika virus

Lyme disease is caused by Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart and the nervous system.
Zika virus is transmitted to humans primarily through the bite of an infected Aedes species mosquito. The most common symptoms of Zika are fever, rash, joint pain and conjunctivitis (red eyes). Because the symptoms of Zika are similar to those of many other diseases, many cases may not have been recognized. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil and on February 1, 2016, the World Health Organization (WHO) declared Zika a public health emergency of international concern (PHEIC). Local transmission has been reported in many other countries and territories. Zika likely will continue to spread to new areas.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details Evolva

Neil Goldsmith,CEO
neilg@evolva.com
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO
jakobdh@evolva.com
+ 41 61 485 2034

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

THIS PRESS RELEASE CONTAINS SPECIFIC FORWARD-LOOKING STATEMENTS, E.G. STATEMENTS INCLUDING TERMS LIKE BELIEVE, ASSUME, EXPECT OR SIMILAR EXPRESSIONS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY RESULT IN A SUBSTANTIAL DIVERGENCE BETWEEN THE ACTUAL RESULTS, FINANCIAL SITUATION, DEVELOPMENT OR PERFORMANCE OF THE COMPANY AND THOSE EXPLICITLY OR IMPLICITLY PRESUMED IN THESE STATEMENTS. AGAINST THE BACKGROUND OF THESE UNCERTAINTIES READERS SHOULD NOT PLACE UNDUE RELIANCE ON FORWARD-LOOKING STATEMENTS. THE COMPANY ASSUMES NO RESPONSIBILITY TO UPDATE FORWARD-LOOKING STATEMENTS OR TO ADAPT THEM TO FUTURE EVENTS OR DEVELOPMENTS

aravis news image

July 20, 2016

Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and expands its Scientific Advisory Board

AMSTERDAM , July 20th 2016 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.

“Improvement in the therapeutic index is a key metric in the quest for superior ADCs. What is exciting about our technology is that we can now consistently demonstrate in preclinical models of liquid and solid…

READ MORE

AMSTERDAM , July 20th 2016 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.

“Improvement in the therapeutic index is a key metric in the quest for superior ADCs. What is exciting about our technology is that we can now consistently demonstrate in preclinical models of liquid and solid tumors that if we connect the same antibody and payload from each commercially-available ADC product using our proprietary technology, we are able to increase the efficacy of the drug as well as its safety and tolerability. These data confirm our experimental findings to date and highlight the potential of our technology to address the persistent unmet medical need across a wide variety of cancer types,” said Dr. Floris van Delft, CSO of Synaffix.

Together with this data, Synaffix today announced the expansion of its Scientific Advisory Board with the addition of Dr. George W. Sledge, the Chief of Medical Oncology at Stanford University Medical Center and former President of the American Society of Clinical Oncology.

“It is an honor to join the SAB at such an important time in the Company’s history. The preclinical data package of Synaffix has demonstrated, in multiple cancer types now, the ability of the technology to produce differentiated targeted cancer therapeutics. I look forward to further supporting the Company as it undertakes the translation of its platform technology into clinical ADC programs,” said Dr. Sledge.

GlycoConnect™ and HydraSpace™

The Synaffix technology platforms include GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation reagents, and HydraSpace™, the ADC-enhancing spacer technology. GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an ADC on its own. The highly polar properties of HydraSpace® improve the solubility and stability of the payload and the resulting ADC product, thus enhancing further the therapeutic index of the ADC. Both technologies have demonstrated compatibility with all ADC payload classes and all IgG isotypes without requiring antibody engineering.

About Synaffix BV

Founded in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms.

As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure™.

Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures, the strategic corporate venture capital fund of Merck.

Contact

Anthony DeBoer
Director, Business Development
Synaffix BV
bd@synaffix.com

aravis news image

May 26, 2016

Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides

Enabling patent key to the commercial expansion of and broader access to stevia sweeteners

Reinach, 26 May 2016 – Evolva (SIX: EVE) announces that the European Patent Office has granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived steviol glycosides.

At the heart of this enabling IP lies a novel technique for converting rebaudioside A (Reb A) to the best tasting, and as a result most commercially relevant, rebaudioside D (Reb D) and rebaudioside M (Reb M) ingredients through fermentation.

Evolva was the first company to discover the enzymes capable of carrying out the key unknown steps in the Reb A and Reb D biosynthesis pathways. This discovery enables the production of these steviol glycosides through bioprocessing, solving the taste and cost conundrum of stevia sweeteners that has…

READ MORE

Enabling patent key to the commercial expansion of and broader access to stevia sweeteners

Reinach, 26 May 2016 – Evolva (SIX: EVE) announces that the European Patent Office has granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived steviol glycosides.

At the heart of this enabling IP lies a novel technique for converting rebaudioside A (Reb A) to the best tasting, and as a result most commercially relevant, rebaudioside D (Reb D) and rebaudioside M (Reb M) ingredients through fermentation.

Evolva was the first company to discover the enzymes capable of carrying out the key unknown steps in the Reb A and Reb D biosynthesis pathways. This discovery enables the production of these steviol glycosides through bioprocessing, solving the taste and cost conundrum of stevia sweeteners that has limited their broader commercial use.

Evolva currently has 54 patents pending around the world related to yeast fermentation-derived steviol glycosides. With the addition of this most recent patent, Evolva now has four commercially relevant stevia sweetener patents granted.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details

Neil Goldsmith,CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Luc Gruner, Commercial
lucg@evolva.com
+ 41 79 575 2361

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

aravis news image

May 12, 2016

Novimmune doubles down in HLH; second $31M round this year

Dublin, Thursday, May 12, 2016 – Novimmune SA closed a CHF30 million (US$31 million) funding round, taking the total cash it has raised this year to CHF60 million and its lifetime total to more than CHF300 million.

The Geneva-based firm is doubling down on its lead program in primary hemophagocytic lymphohistiocytosis (HLH), a rare and devastating dysfunction of the immune system, which has a fatality rate of about 50 percent. Novimmune gained FDA breakthrough therapy designation in March for NI-0501, a fully human antibody that targets interferon gamma, the pleiotropic pro-inflammatory cytokine that modulates innate and adaptive immune responses. It is now close to completing recruitment in a pivotal phase II/III trial.

“Our current expectation is we can file in 2017 – most likely early in the second quarter. If it goes very well, maybe in the first quarter,” Chairman and CEO Ed Holdener told BioWorld Today.

The company had been considering…

READ MORE

Dublin, Thursday, May 12, 2016 – Novimmune SA closed a CHF30 million (US$31 million) funding round, taking the total cash it has raised this year to CHF60 million and its lifetime total to more than CHF300 million.

The Geneva-based firm is doubling down on its lead program in primary hemophagocytic lymphohistiocytosis (HLH), a rare and devastating dysfunction of the immune system, which has a fatality rate of about 50 percent. Novimmune gained FDA breakthrough therapy designation in March for NI-0501, a fully human antibody that targets interferon gamma, the pleiotropic pro-inflammatory cytokine that modulates innate and adaptive immune responses. It is now close to completing recruitment in a pivotal phase II/III trial.

“Our current expectation is we can file in 2017 – most likely early in the second quarter. If it goes very well, maybe in the first quarter,” Chairman and CEO Ed Holdener told BioWorld Today.

The company had been considering an IPO back in January, but, given the weakening market conditions, its investors decided to build the company’s value by funding the generation of more clinical data. Partnering discussions are ongoing – and a trade sale is “always a possibility,” Holdener said – but the company is not actively working on an IPO at present.

Gaining the FDA designation boosted investor confidence in the company. Seeking it involved a certain amount of risk, Holdener said, as rare disease programs at small, unlisted companies do not match the typical profile for breakthrough therapies. Oncology programs – or infectious disease programs – at larger, quoted firms are the norm.

HLH is, he said, “an ultra-rare disease.” It has a prevalence of about one in 50,000. It can be caused by mutations in several genes involved in regulating immune cell functions, including PRF1, UNC13D, STX11 and STXBP2. The gene involved in a fifth subtype, designated HLH subtype 1, has yet to be identified, according to the NIH’s Genetic and Rare Diseases Information Center.

There are no drugs approved for HLH. Current regimens involve highly toxic cytotoxic and immunosuppressive therapy, which are administered with the aim of achieving remission so that patients can undergo bone marrow transplant. “Bone marrow transplant in mutation-driven primary HLH is the only potentially curative approach, ultimately,” Holdener said.

A long-term study of the HLH-94 treatment protocol, which involves co-administration of etoposide and dexamethasone, in 249 patients with primary or acquired HLH achieved a five-year survival rate of 54 percent (± 6 percent). The survival rate for patients with familial HLH was 50 percent (± 13 percent). No patient who did not undergo bone marrow transplant survived. The data appeared in the Oct. 27, 2011, issue of Blood, in a paper, titled “Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.”

Novimmune reported promising preliminary data from an open-label phase II study of NI-0501 at the American Society for Hematology meeting in December. Of 13 patients with advanced disease, 10 responded to therapy – seven underwent bone marrow transplant and two more were scheduled to do so, once suitable donors were identified. A 10th patient – the only one to receive NI-0501 as a first-line therapy – also attained good disease control but was not designated to receive a bone marrow transplant owing to the absence of a causative genetic mutation. Eleven of the 13 remained alive at eight weeks.

In familial disease, NI-0501 has the potential to reduce the toxic burden on patients and enable them to progress to bone marrow transplant more easily. It also has potential – yet to be explored in the clinic – in managing acquired HLH, which can arise from complications following infection, autoimmune disease or hematological malignancy.

The company has three other clinical-stage programs, two of which are out-licensed. The Genentech arm of Roche AG, of Basel, Switzerland, is developing NI-1401, an anti-interleukin-17 antibody, for autoimmune indications. London-based Tiziana Life Sciences plc has in-licensed foralumab (NI-0401), which targets the epsilon chain of the T-cell receptor CD3, for autoimmune indications. An unpartnered antibody targeting Toll-like receptor 4 is ready to enter a phase II proof-of-concept study in rheumatoid arthritis. Novimmune is seeking a deal for that program.

Its most advanced bispecific molecule, NI-1701, which targets CD19 and CD47, is in development for B-cell leukemia and lymphoma and is ready to enter the clinic next year

aravis news image

April 11, 2016

Evolva to co-develop next-generation materials with US Navy

Applications include fire resistant coatings and structural materials for use in aircraft, waterborne craft, fabrics and construction

Reinach, 11 April 2016 – Evolva (SIX: EVE) announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential commercialisation of new lightweight, fire-resistant composite materials to save lives and reduce harm from fire.

Applications of these advanced materials include aircraft, waterborne craft, fabrics, armoured vehicles, and construction materials. These next-generation composite materials are based on a molecule that can be manufactured on an industrial scale using advanced biotechnology and fermentation, and then polymerised and shaped/moulded using standard fabrication techniques.

If successful, this…

READ MORE

Applications include fire resistant coatings and structural materials for use in aircraft, waterborne craft, fabrics and construction

Reinach, 11 April 2016 – Evolva (SIX: EVE) announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential commercialisation of new lightweight, fire-resistant composite materials to save lives and reduce harm from fire.

Applications of these advanced materials include aircraft, waterborne craft, fabrics, armoured vehicles, and construction materials. These next-generation composite materials are based on a molecule that can be manufactured on an industrial scale using advanced biotechnology and fermentation, and then polymerised and shaped/moulded using standard fabrication techniques.

If successful, this project would create for the US Navy novel composite materials that are fire resistant, stronger and lighter than aluminium, and capable of withstanding high temperatures. These materials would also be more sustainably sourced, less expensive, and offer a number of other advantages over existing composites.

“This agreement highlights and validates the versatility of our product innovation platform and depth of our plant science expertise,” said Evolva CEO Neil Goldsmith. “This CRADA also illustrates just how far and wide Evolva is making inroads across multiple industries with its building-with-biology platform.”

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details Evolva

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

aravis news image

April 5, 2016

Evolva gains exclusive license to develop and commercialise nootkatone globally for pest control

Evolva also signs broader nootkatone collaboration agreement with CDC

Reinach, 5 April 2016 – Evolva (SIX: EVE) announces that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control of a wide range of disease and virus vectors such as ticks, mosquitoes, fleas, flies, lice, bed bugs, and other biting insects.

Evolva announced just recently that it is expanding its nootkatone research focus to include the mosquitoes that transmit Zika and other viruses. This expanded focus is included in the comprehensive Cooperative Research and Development Agreement (CRADA) now in place between Evolva and the CDC. The World Health Organisation (WHO) recently declared Zika virus a global public health emergency. Nootkatone could play an important role in the global response to the spread of Zika.

CDC research has shown…

READ MORE

Evolva also signs broader nootkatone collaboration agreement with CDC

Reinach, 5 April 2016 – Evolva (SIX: EVE) announces that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control of a wide range of disease and virus vectors such as ticks, mosquitoes, fleas, flies, lice, bed bugs, and other biting insects.

Evolva announced just recently that it is expanding its nootkatone research focus to include the mosquitoes that transmit Zika and other viruses. This expanded focus is included in the comprehensive Cooperative Research and Development Agreement (CRADA) now in place between Evolva and the CDC. The World Health Organisation (WHO) recently declared Zika virus a global public health emergency. Nootkatone could play an important role in the global response to the spread of Zika.

CDC research has shown nootkatone both repels and kills the yellow fever mosquito, Aedes aegypti, and the black-legged tick, Ixodes scapularis which transmits Lyme disease. Nootkatone appears to have a mode of action distinct from that of currently used pesticides and therefore could potentially be valuable for mitigating pesticide resistance in mosquito vectors. Nootkatone already occurs in the natural environment and has an established track record as a flavor and fragrance ingredient, providing attractive characteristics in a number of respects.

Nootkatone can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the Nootka cypress), or produced on an industrial scale from brewing via yeast fermentation. Evolva is currently performing all necessary safety and efficacy studies to get nootkatone approved by the US Environmental Protection Agency, initially as a repellent against the blacklegged tick.

“We now have the tools in place to accelerate the research and commercial development of nootkatone as a next-generation pest control compound against a broad range of biting insects, including the mosquitoes that transmit Zika, chikungunya, dengue, and West Nile viruses,” said Evolva CEO Neil Goldsmith.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details Evolva

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO
jakobdh@evolva.com
+ 41 61 485 2034

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

 

Aravis News

March 11, 2016

Jean-Philippe Tripet speaks about the start-up scene in Switzerland

Institutions and Start-ups in Switzerland

Filling the Double Gap

While Switzerland is very proud of its leading position in innovation ranking, a comparison with peer countries shows that we are poor in commercialising this excellent science (Gap 1). Jean-Philippe Tripet CFA, to discuss Aravis’ research showing that Switzerland invests 3 times less than Sweden and 6 times less than Israel in start-ups. With 200-300 start-ups per year, there is no deal flow issue. However, there is clear evidence that we significantly lack investment in new venture and small companies (Gap 2).

Finding the first million from Angels, family friends and fools is relatively easy, but the depth of the Valley of Death (finding the next Fr. 20 million) is much more significant than in other countries. A number of political initiatives to support start-ups have been launched on the last three years, the most prominent being the Motion Graber and Postulat Derder.…

READ MORE

Institutions and Start-ups in Switzerland

Filling the Double Gap

While Switzerland is very proud of its leading position in innovation ranking, a comparison with peer countries shows that we are poor in commercialising this excellent science (Gap 1). Jean-Philippe Tripet CFA, to discuss Aravis’ research showing that Switzerland invests 3 times less than Sweden and 6 times less than Israel in start-ups. With 200-300 start-ups per year, there is no deal flow issue. However, there is clear evidence that we significantly lack investment in new venture and small companies (Gap 2).

Finding the first million from Angels, family friends and fools is relatively easy, but the depth of the Valley of Death (finding the next Fr. 20 million) is much more significant than in other countries. A number of political initiatives to support start-ups have been launched on the last three years, the most prominent being the Motion Graber and Postulat Derder. Swiss Parliament as well as the Swiss Federal Government have voted in favour of the motion, however, a year later where are we?

• What initiatives are in discussion
• What have pensions funds done?
• Will Switzerland ever manage to boost investments in small companies to stay competitive.

In an environment where globalisation is here to stay and a country highly dependent on exports with a very strong currency, the metrics of past success will not apply to the future. Old sectors unable to match the new environment will need to make space to new sectors where new global leaders will emerge. Switzerland has the ingredients of a very strong academic backbone, well educated digital-native generation and a liberal environment. We must praise risk-taking entrepreneurs and by that, evolve our culture. Critical to this success will be to address our weaknesses honestly, and build bridges to link capital markets, innovations and entrepreneurs.

Jean-Philippe Tripet CFA
Managing Partner and Founder of Aravis

As a participant in the CFA Institute Approved-Provider Program, the CFA Society Switzerland has determined that this event qualifies for one credit hour of CE. If you are a CFA Institute Member, CE credit for your attendance at this event will be automatically recorded in your CE.